OOIR: Observatory of International Research

Papers

(The TQCC of Cancer Biology & Medicine is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Multiplex imaging reveals the architecture of the tumor immune microenvironment	133
Emerging roles of plasmacytoid dendritic cell crosstalk in tumor immunity	66
Therapeutic revolution for inoperable stage III non-small cell lung cancer in the immune era	42
Peptide drugs: a new direction in cancer immunotherapy	42
The choice of a neoadjuvant chemotherapy cycle for breast cancer has significance in clinical practice: results from a population-based, real world study	39
Hot issues in triple-negative breast cancer	37
Drug clinical trials on high-grade gliomas: challenges and hopes	34
Metabolic regulation of innate immunity in cancer immunotherapy	32
Highlighted multi-modifications of enzymes: a novel succinylation mediated by histone acetyltransferase 1 in tumors	32
Recent advances in the systemic treatment of gastrointestinal stromal tumors	24
Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy	23
The interplay between H3K36 methylation and DNA methylation in cancer	20
A causal variant rs3769823 in 2q33.1 involved in apoptosis pathway leading to a decreased risk of non-small cell lung cancer	19
Blockade of CD300A enhances the ability of human NK cells to lyse hematologic malignancies	19
Revolutionizing tumor immunotherapy: unleashing the power of progenitor exhausted T cells	19
Super-enhancer receives signals from the extracellular matrix to induce PD-L1-mediated immune evasion via integrin/BRAF/TAK1/ERK/ETV4 signaling	19
Evolving molecular subtyping of breast cancer advances precision treatment	18
Potential new applications of immunotherapy for neuroendocrine neoplasms: immune landscape, current status and future perspectives	18
DNA damage response-related immune activation signature predicts the response to immune checkpoint inhibitors: from gastrointestinal cancer analysis to pan-cancer validation	18
The outpost against cancer: universal cancer only markers	17
JaponiconeA induces apoptosis of bortezomib-sensitive and -resistant myeloma cells in vitro and in vivo by targeting IKKβ	17
Progress on immuno-microenvironment and immune-related therapies in patients with pseudomyxoma peritonei	16
Single-arm trials for domestic oncology drug approvals in China	16
Cancer risk in relatives of BRCA1/2 pathogenic variant carriers in a large series of unselected patients with breast cancer	16
Advances in MET tyrosine kinase inhibitors in gastric cancer	15

Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance	15
Next-generation antibody–drug conjugates revolutionize the precise classification and treatment of HER2-expressing breast cancer	15
IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation	13
Circulating cell-free mtDNA as a new biomarker for cancer detection and management	12
Using triple radio-immunotherapy to overcome cancer immunotherapy resistance	12
Comprehensive characterization of CRC with germline mutations reveals a distinct somatic mutational landscape and elevated cancer risk in the Chinese population	12
Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer	11
Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma	11
Optimal immunotherapy duration in advanced NSCLC: defining the ideal treatment window	11
Comparative profiling of immune genes improves the prognoses of lower grade gliomas	10
Update on diffuse large B-cell lymphoma: highlights from the 2022 ASCO Annual Meeting	9
Epigenetic reprogramming in small cell lung cancer	9
The role of DLL1 in long-term vascular normalization and cancer immunotherapy	8
Impact of cancer diagnosis on life expectancy by area-level socioeconomic groups in New South Wales, Australia: a population-based study	8
Microsurgery vs. radiosurgery for the treatment of multiple metastases in the brain: a retrospective cohort study	8
Expanding horizons in overcoming therapeutic resistance in castration-resistant prostate cancer: targeting the androgen receptor-regulated tumor immune microenvironment	8
Research progress in hepatitis B virus covalently closed circular DNA	8
Roles of eIF5A in the immunosurveillance of cellular senescence	8
Complex role of neutrophils in the tumor microenvironment: an avenue for novel immunotherapies	8
DB-1310, a HER3-targeting antibody-drug conjugate, has synergistic anti-tumor activity with trastuzumab in HER2- and HER3-expressing breast cancer	8
Metabolic regulation of immune responses to cancer	8
Effectiveness of colorectal cancer screening integrating non-genetic and genetic risk: a prospective study based on UK Biobank data	7
Safety and efficacy of intraoperative radiation therapy using a low-energy X-ray source for resectable pancreatic cancer: an interim evaluation of an ongoing prospective phase II study	7
Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification	7
Cohort profile: design and methods of the Chinese colorectal, breast, lung, liver, and stomach cancer screening trial (C-BLAST)	7
Intercellular transmission of cGAS-STING signaling in cancer	7
Clinical management and survival outcomes of patients with different molecular subtypes of diffuse gliomas in China (2011–2017): a multicenter retrospective study from CGGA	7
EZH2 identifies the precursors of human natural killer cells with trained immunity	7
Bacterial outer membrane vesicle-based cancer nanovaccines	7
Development of small molecule drugs targeting immune checkpoints	6
Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up	6
2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma	6
The Warburg effect drives dedifferentiation through epigenetic reprogramming	6
Early detection of gastric cancer in China: progress and opportunities	6
Targeting the EGF receptor family in non-small cell lung cancer—increased complexity and future perspectives	6
Frequent low dose alcohol intake increases gastric cancer risk: the Health Examinees-Gem (HEXA-G) study	6
Single-cell RNA sequencing reveals spatial heterogeneity and immune evasion of circulating tumor cells	5
PD-1 inhibitors provide new opportunities in conversion therapy for stage IV gastric cancer	5
Artificial intelligence strengthenes cervical cancer screening – present and future	5
Improved treatment of colorectal liver metastases by early response evaluation and regimen adjustment: a prospective study of clinical functional MR-based modeling	5
Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II tria	5
Efficacy and safety of anlotinib combined with the STUPP regimen in patients with newly diagnosed glioblastoma: a multicenter, single-arm, phase II trial	5
Progress in oncolytic viruses modified with nanomaterials for intravenous application	5
The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKKα and overcomes gefitinib resistance in non-small cell lung cancer	5
Roles of cancer-associated fibroblast functional heterogeneity in shaping the lymphatic metastatic landscape: new insights and therapeutic strategies	5
Chinese Society of Clinical Oncology Non-small Cell Lung Cancer (CSCO NSCLC) guidelines in 2024: key update on the management of early and locally advanced NSCLC	5
Circular RNAs: implications of signaling pathways and bioinformatics in human cancer	5
Platinum is essential in neoadjuvant treatment of triple-negative breast cancer: a network meta-analysis	5
Genetic polymorphisms in genes regulating cell death and prognosis of patients with rectal cancer receiving postoperative chemoradiotherapy	5
Role of the tumor microenvironment in shaping IDH-wildtype glioma plasticity, and potential therapeutic strategies	5

Cancer immunology and immunotherapy	5
The active surveillance management approach for patients with low risk papillary thyroid microcarcinomas: is China ready?	5
Understanding the mechanisms underlying obesity in remodeling the breast tumor immune microenvironment: from the perspective of inflammation	5
Stability and variability of molecular subtypes: comparative analysis of primary and metastatic triple-negative breast cancer	4
The mutation landscape of multiple cancer predisposition genes in Chinese familial/hereditary breast cancer families	4
ACSL3 regulates breast cancer progression via lipid metabolism reprogramming and the YES1/YAP axis	4
Deep-learning methods for unveiling large-scale single-cell transcriptomes	4
Inconsistent radiotherapy effects between primary tumors and axillary lymph nodes	4
Optimizing the cancer research landscape for the benefit of patients and society: A strategic perspective of the German Cancer Research Center (DKFZ) and its partnerships with university medical cente	4
Reflections on the withdrawal of medical articles and the development of writing and publishing standards	4
Prognostic significance of a combined and controlled nutritional status score and EBV-DNA in patients with advanced nasopharyngeal carcinoma: a long-term follow-up study	4
Associations between polymorphisms in leptin and leptin receptor genes and colorectal cancer survival	4
Diagnosis of malnutrition in cancer patients	4
Bile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma	4
Multifaceted efforts of governments, medical institutions, and financial organizations contribute to reducing the health inequality caused by economic differences	4
Precision medicine in the treatment of colorectal cancer with liver metastases	4
Multiple myeloma survival in New South Wales, Australia, by treatment era to 2020	4
Enhancement of anti-PD-L1 antibody plus anlotinib efficacy due to downregulation of PD-L1 in the micro-conduit endothelium within the tumor: a randomized double-blind trial	4
SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation	4